Login / Signup

Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study.

Kosuke EbinaToru HiranoYuichi MaedaWataru YamamotoMotomu HashimotoKoichi MurataAkira OnishiSadao JinnoRyota HaraYonsu SonHideki AmuroTohru TakeuchiAyaka YoshikawaMasaki KatayamaKeiichi YamamotoMakoto HiraoYasutaka OkitaAtsushi KumanogohKen Nakata
Published in: Clinical rheumatology (2021)
After adjustment by potent confounders, SAR, BAR, and TOF showed similar discontinuation rates due to lack of effectiveness and toxic adverse events. Key Points • This is the first retrospective multicenter study that aimed to clarify the retention rates and reasons for discontinuation of SAR, BAR, and TOF in patients with RA.
Keyphrases
  • mass spectrometry
  • ms ms
  • rheumatoid arthritis
  • randomized controlled trial
  • systematic review
  • disease activity
  • emergency department
  • anti inflammatory
  • ankylosing spondylitis
  • drug induced
  • electronic health record